Skip to main content
03.23 Published Article

A Randomized, Placebo-Controlled Pilot Study of Upamostat, a Host-Directed Serine Protease Inhibitor, for Outpatient Treatment of COVID-19

Related Professionals
Danielle Abramson, Ph.D.
Capabilities
Intellectual Property & Technology Patents and Innovation Strategies Life Sciences & Medical Technology
Offices
Boston

Danielle Abramson authored "A Randomized, Placebo-Controlled Pilot Study of Upamostat, a Host-Directed Serine Protease Inhibitor, for Outpatient Treatment of COVID-19" for the International Journal of Infectious Diseases.

LINKS

Read "A Randomized, Placebo-Controlled Pilot Study of Upamostat, a Host-Directed Serine Protease Inhibitor, for Outpatient Treatment of COVID-19."

You May Also Be Interested In:
March 12, 2026 Press Release
Greenberg Traurig Represents CoviMedical in recovery proceedings brought by the Association of Statutory Health Insurance Physicians in Hesse, Germany 1 min read
02.26 Published Article
Force Majeure Clauses and Common Law Defenses in Commercial Real Estate Transactions (IL) Less than a minute
LexisNexis Practical Guidance
February 16, 2024 GT Alert
IRS Determines Third-Party Payers Liable for Clawback of Improper Employee Retention Credit Refunds to Clients 3 min read